United Therapeutics (NASDAQ:UTHR) CEO Sells $5,397,045.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $568.11, for a total transaction of $5,397,045.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $23,015,840.43. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Down 0.5%

NASDAQ UTHR opened at $563.93 on Thursday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock has a market capitalization of $23.94 billion, a PE ratio of 20.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. The firm has a 50 day moving average of $562.18 and a two-hundred day moving average of $510.32.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the company posted $6.63 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. On average, equities research analysts expect that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on UTHR shares. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. TD Cowen upped their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently made changes to their positions in UTHR. Avoro Capital Advisors LLC grew its stake in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP grew its stake in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC grew its stake in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the last quarter. Janus Henderson Group PLC grew its stake in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares during the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in United Therapeutics in the 3rd quarter valued at about $317,617,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.